CXCL8 and Arthritis: Most notable increases included IL-6 (BTB, 0.740 ± 0.014, DMSO, 0.054 ± 0.011, P-adj = 0.0068; Fig. 7B), already a therapeutic target in arthritis (63) and IL-8 (BTB, 0.667 ± 0.001, DMSO, 0.066 ± 0.020, P-adj = 0.001; Fig. 7B), which is elevated in arthritic disease and has been shown to coordinate immune cell infiltration (64).